Phase i study of the heat shock protein 90 inhibitor alvespimycin (KOS-1022, 17-DMAG) administered intravenously twice weekly to patients with acute myeloid leukemia

J. E. Lancet, I. Gojo, M. Burton, M. Quinn, S. M. Tighe, K. Kersey, Z. Zhong, M. X. Albitar, K. Bhalla, A. L. Hannah, M. R. Baer

Research output: Contribution to journalArticlepeer-review

Fingerprint Dive into the research topics of 'Phase i study of the heat shock protein 90 inhibitor alvespimycin (KOS-1022, 17-DMAG) administered intravenously twice weekly to patients with acute myeloid leukemia'. Together they form a unique fingerprint.

Medicine & Life Sciences